Stern H
Postgrad Med J. 1977 Oct;53(624):588-91. doi: 10.1136/pgmj.53.624.588.
About 0.5% of infants are infected in utero with cytomegalovirus (CMV). As many as 20% become mentally retarded and a further substantial proportion suffer lesser degrees of brain damage. The need for a vaccine is greater than in the case of rubella. A live, tissue culture-adapted strain of CMV has been shown to produce neutralizing antibody in volunteers without significant side effects or detectable virus excretion. The problems of developing such a vaccine for use in man, namely, attenuation, antigenic differences among virus strains, reactivation of latent infection and oncogenicity, are briefly discussed.
约0.5%的婴儿在子宫内感染巨细胞病毒(CMV)。多达20%的婴儿会智力发育迟缓,另有相当一部分会遭受程度较轻的脑损伤。对CMV疫苗的需求比对风疹疫苗的需求更大。一种经组织培养适应的CMV活毒株已被证明能在志愿者体内产生中和抗体,且无明显副作用或可检测到的病毒排泄。本文简要讨论了开发这种用于人类的疫苗所面临的问题,即减毒、病毒株间的抗原差异、潜伏感染的激活和致癌性。